Antibody Production Recombinant DNA Technology 
Pharmaceutical Technology
FEBRUARY 24, 2023
Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology. The drug candidate is a bi-specific monoclonal antibody that targets EGFr and cMet with exon-20 insertion. It is based on DuoBody technology platform.
Roots Analysis
JANUARY 21, 2024
With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Packaging Solutions
JUNE 30, 2023
Biopharmaceuticals, also called biologics, are drug products that are manufactured using biological sources. There are a few major classes of biopharma products, including the following: Extracted: Biologics extracted directly from living systems (of either animals or humans) are the oldest form of biopharmaceuticals.
Cloudbyz
MARCH 6, 2024
Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology. This allows for the creation of highly specific and targeted therapies that can modulate biological pathways with remarkable precision.
The Pharma Data
JULY 11, 2021
TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Please consult the TAKHZYRO Summary Product Characteristics (SmPC) before prescribing.?. Warnings and Precautions.
Expert insights. Personalized for you.
100 
Let's personalize your content